Efficacy of Trastuzumab Emtansine Therapy in Sequantial Treatment in Patients with HER2-Positive Metastatic Breast Cancer
Abstract views: 99
/ 
PDF downloads: 49
DOI:
https://doi.org/10.5281/zenodo.7931256Keywords:
Breast cancer, HER-2, Pertuzumab, Trastuzumab emtansineAbstract
Aim: The aim of this study was to evaluate the efficacy of Lapatinib, trastuzumab emtansine (T-DM1) treatment after pertuzumab in patients with HER2-positive metastatic breast cancer.
Materials and Methods: The study included HER2-positive breast cancer patients who were followed up and treated in Adana City Training and Research Hospital. Totally 1840 patients with a diagnosis of breast cancer in the hospital management system were evaluated, 670 patients who were determined to be metastatic were evaluated for eligibility. Thirty-one patients who received pertuzumab before T-DM1 treatment, while 34 patients who received T-DM1 before pertuzumab were included.
Results: Of the 65 female patients included in the study, 59 had ductal adenocarcinoma (90.8%) and 6 had lobular adenocarcinoma (9.2%). Seventeen patients (26.2%) had bone metastases, 20 patients (30.7%) had visceral metastases, and 28 patients (43.1%) had bone and visceral metastases together. Overall survival (OS) was 23.8±3 months in those who did not receive pertuzumab before T-DM1 in the metastatic setting, while it was similar in those who received pertuzumab with 22.4±2.9 months (p=0.969). Progression-free survival (PFS) was 9.1±1.3 months in those who did not receive pertuzumab before T-DM1 in the metastatic setting, while it was significantly lower in patients who received pertuzumab with 4.9±0.8 months (p=0.005). The comparison of initiation of T-DM1 after pertuzumab as second-line therapy in the metastatic setting and its use in later therapeutic lines revealed no difference in PFS and OS (p=0.628 and p=0.706, respectively).
Conclusion: Pertuzumab should be preferred primarily because it is more effective in metastatic HER2-positive breast cancer. Despite the significant decrease in PFS of patients using T-DM1 after pertuzumab, there was no decrease in OS; therefore the earlier T-DM1 therapy is initiated following pertuzumab, the more effective it is.
References
Arribas, J., Baselga, J., Pedersen, K., Parra-Palau, J. L. (2011). p95HER2 and Breast Cancer: Figure 1. Cancer Research, 71(5), 1515-1519. https://doi.org/10.1158/0008-5472.CAN-10-3795
Capelan, M., Pugliano, L., De Azambuja, E., Bozovic, I., Saini, K. S., Sotiriou, C.,…Piccart-Gebhart, M. J. (2013). Pertuzumab: New hope for patients with HER2-positive breast cancer. Annals of Oncology, 24(2), 273-282. https://doi.org/10.1093/annonc/mds328
Hudis, C. A. (2007). Trastuzumab—Mechanism of Action and Use in Clinical Practice. New England Journal of Medicine, 357(1), 39-51. https://doi.org/10.1056/NEJMra043186
Michel, L. L., Hartkopf, A. D., Fasching, P. A., Kolberg, H.-C., Hadji, P., Tesch, H., …Fehm, T. N. (2020). Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 12(10), 3021. https://doi.org/10.3390/cancers12103021
Perez, E.A., Barrios C., Eiermann, W., Toi, M., Im, Y.H., Conte, P.,… Ellis, P.( 2017). “Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study”. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 35(2):141-48. doi: 10.1200/JCO.2016.67.4887.
Sjögren, S., Inganäs, M., Lindgren, A., Holmberg, L., Bergh, J. (1998). Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. Journal of Clinical Oncology, 16(2), 462-469. https://doi.org/10.1200/JCO.1998.16.2.462
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. (1987). Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene. Science, 235(4785), 177-182. https://doi.org/10.1126/science.3798106
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E.,…Press, M. F. (1989). Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer. Science, 244(4905), 707-712. https://doi.org/10.1126/science.2470152
Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., …Borresen-Dale, A.-L. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences, 98(19), 10869-10874. https://doi.org/10.1073/pnas.191367098
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A.,…Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71(3), 209-249. https://doi.org/10.3322/caac.21660
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M.,…Cortés, J. (2015). Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 372(8), 724-734. https://doi.org/10.1056/NEJMoa1413513
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J.,…Blackwell, K. (2012). Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. New England Journal of Medicine, 367(19), 1783-1791. https://doi.org/10.1056/NEJMoa1209124
Vici, P., Pizzuti, L., Michelotti, A., Sperduti, I., Natoli, C., Mentuccia, L., …Gamucci, T. (2017). A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience. Oncotarget, 8(34), 56921-56931. https://doi.org/10.18632/oncotarget.18176
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 GEVHER NESIBE JOURNAL OF MEDICAL AND HEALTH SCIENCES
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The journal is licensed under a 